Modelling the spread of hepatitis C via commercial tattoo parlours: Implications for public health interventions

OR Spectrum

Volumn 30, Issue 2, 2008, Pages 269-288

  Behrens, Doris A ^a   Rauner, Marion S ^b   Caulkins, Jonathan P ^c,d  

^a VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d Qatar Campus ^*  (Qatar)

Author keywords

Commercial tattoo parlours; Cost effectiveness; Dynamic modelling; HCV epidemic; Policy analysis

Indexed keywords

EID: 43049116159     PISSN: 01716468     EISSN: 14366304     Source Type: Journal    
DOI: 10.1007/s00291-007-0090-7     Document Type: Article

References (45)

1. Alter MJ (2002) Prevention of spread of hepatitis C. Hepatology 36(5 Suppl 1):S93-S98
2. American Gastroenterological Association (2003) Stigma of hepatitis C and lack of awareness stops Americans from getting tested and treated. AGA News Releases
3. Anderson RM, May RM (1991) Infectious diseases of humans. Oxford University Press, Oxford
4. Armstrong ML, Murphy KP (1997) Tattooing: another adolescent risk behavior warranting health education. Appl Nurs Res 10(4):181-189
5. Armstrong ML, Roberts AE, Owen DC, Koch JR (2004) Contemporary college students and body piercing. J Adolescent Health 35(1):58-61
6. Armstrong GL, Simard EP, Wasley A, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus (HCV) infection in the United States, 1999-2002. Ann Internal Med 144(10):705-714
7. Balasekaran R, Bulterys M, Jamal MM, Quinn PG, Johnston DE, Skipper B, Chaturvedi S, Arora S (1999) A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. Am J Gastroenterol 94(5):1341-1346
8. Blaschke S, Purkert T (2004) Das ökonomische Potential von Präventionsmaßnahmen im Bereich Hepatitis C: Die Rolle der Tattoo-Studios. Master Thesis. University of Vienna, Austria
9. Centers for Disease Control and Prevention (1998) Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morbid Mortal Wkly Rep 47(RR-19):1-33
10. Centers for Disease Control and Prevention (2004) Hepatitis surveillance report no 59. US Department of Health and Human Services, CDC, Atlanta
11. Centers for Disease Control and Prevention (2005) Health Information for International Travel 2005-2006. Department of Health and Human Services, CDC, Atlanta
12. Commonwealth of Australia (2005) National hepatitis C strategy. 2005-2008. Publication approval number 3642 (JN9005). ISBN 0-642-82656-0
13. Desenclos JC (2003) The challenge of hepatitis C surveillance in Europe. Euro Surv 8(5):99-100
14. Deuffic-Burban S, Poynard T, Valleron AJ (2002) Quantification of fibrosis progression in patients with chronic hepatitis C using a markov model. J Viral Hepatitis 9(2):114-122
15. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T (2004) Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 40(2):319-326
16. Esposito N, Rossi C (2004) A nested-epidemic model for the spread of hepatitis C among injecting drug users. Math Biosci 188:29-45
17. Federal Camber of Employees of the Republic of Austria (2004) Wirtschafts- und Sozialstatistisches Taschenbuch 2004. Federal Camber of Employees, Vienna, Austria
18. Federal Ministry of Economics and Labour of the Republic of Austria (2003) Ausuebungsregeln für das Piercen und Tätowieren durch Kosmetik (Schoenheitspflege)-Gewerbetreibende. BGBl II (Austrian Federal Law Gazette, Part II) 141/2003:647-651
19. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
20. Haley RW, Fischer RP (2001) Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine 80(2):134-151
21. Haley RW, Fischer RP (2003) The tattooing paradox: are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Archives of Internal Medicine 163(9):1095-1098
22. Health Canada (2001) Special report on youth, piercing, tattooing and hepatitis C trendscan findings. Health Canada, Toronto
23. Jacquez J, Koopman J, Perry T, Sattenspiel L, Simon C (1988) Modeling and analyzing HIV transmission: the effect of contact patterns. Math Biosci 92(2):119-199
24. Jonas S, Jessner W, Rafetseder O, Wild C (2004) Chronische Hepatitis C - Implikationen für Therapie und ökonomischen Ressourceneinsatz in Österreich. Institute for Technology Assessment of the Austrian Academy of Sciences, Vienna
25. Kaplan EH, Brandeau M (eds) (1994) Modeling the AIDS epidemic. Raven Press, New York
26. Layden TJ, Layden JE, Ribeiro RM, Perelson AS (2003). Mathematical modeling of viral kinetics: a tool to understand and optimise therapy. Clin Liver Dis 7(1):163-178
27. Mather D, Crofts N (1999) A computer model of the spread of hepatitis C virus among injecting drug users. Eur J Epidemiol 15(1):5-10
28. Mather D (2000) A simulation model of the spread of hepatitis C within a closed cohort. J Oper Res Soc 51(6):656-66
29. Nelson PW, Perelson AS (2002) Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci 179(1):73-94
30. Pollack HA (2001) Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med Decis Making 21(5):357-367
31. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH (2001) The epidemic behavior of the hepatitis C virus. Science 292(5525):2323-2325
32. Rauner MS (2002) Using simulation for AIDS policy modeling: benefits for HIV/AIDS prevention policy makers in Vienna, Austria. Health Care Manage Sci 5(2):121-134
33. Rauner MS, Brailsford SC, Flessa S (2005) The use of discrete-event simulation to evaluate strategies for the prevention of mother-to-child transmission of HIV in developing countries. J Oper Res Soc 56(2):222-233
34. Rauner MS, Behrens DA, Caulkins JP (2004) An epidemic model of the spread of hepatitis C via tattoo parlors: implications for the timing of public health interventions. ORDYS working paper 288, Vienna University of Technology, Vienna, Austria (37 p)
35. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ (2002) Empirically calibrated model of hepatitis C infection in the United States. Am J Epidemiol 156(8):761-773
36. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ (2003) Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patients population. JAMA 290(2):228-237
37. Sheerin IG, Green FT, Sellman JD (2003) The cost of not treating hepatitis C virus infection in injecting drug users in New Zealand. Drug Alcohol Rev 22(2):159-167
38. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, Hutchison JG, Wong JB, German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group (2003) Cost-effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52(3):425-432
39. Statistics Austria (2004) Statistic Yearbook 2004. Statistics Austria, Vienna
40. Struve J, Norrbohm O, Stenbeck J, Giesecke J, Weiland O (1995) Risk factors for hepatitis A, B and C virus infection among Swedish expatriates. J Infect 31(3):205-209
41. Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20(1):1-16
42. Weusten JJ, van Drimmelen HA, Lelie PN (2003) Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 42(5):537-348
43. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U (2000) Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 32(1):91-96
44. World Health Organization (1999a) Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 74(49):425-427
45. World Health Organization (1999b) Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board: Antwerp, Belgium. J Viral Hepat 6(1):35-47